Treatment Approaches

What is IL-2?

A small protein naturally produced by the cells of the immune system, IL-2 stimulates the growth of tumor killing cells. High-dose IL-2 is an approved therapy for advanced melanoma (skin cancer) and advanced renal cell (kidney) cancer.

Patients may receive IL-2 therapy alone or in combination with tumor vaccines. The comprehensive IL-2 Unit of the Tumor Immunotherapy Program administers IL-2 through an intravenous (IV) line on an in-patient basis.

Researchers are also investigating the potential benefits of additional cytokines, including IL-12 and IL-18.

What is Interferon?

A natural protein, Interferon stimulates the body's response to fight infections and possible cancers. Interferon has shown some promise in treating melanoma (skin cancer) and renal cell (kidney) cancer. Interferon is administered either through an IV or an injection into the skin on an outpatient basis.

Am I a candidate for tumor immunotherapy?

The FDA has approved treatment with IL-2 and Interferon for stage III and IV renal cell (kidney) cancer and melanoma (skin cancer).

Additional tumor immunotherapy treatments for breast, colon, kidney, lung, pancreas, and prostate cancer, as well as lymphoma, melanoma, and myeloma, are available through clinical trials. You or your medical oncologist can contact us to determine whether you are eligible to participate. Participation is voluntary and you may withdraw at any time.

For information regarding IL-2 therapy, Interferon therapy, or participation in one of our trials, please contact Gail DeRaffele, RN, Clinical Coordinator, at 212.342.0232 or gd2023@columbia.edu.

Download our Tumor Immunotherapy Brochure (515 KB)